Skip to content
‹ Back to IndustriesSciences

As Spaces Evolves into a “Normal Market”, How Will This Impact the Competition?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration. In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · Space CommerceSpace Commerce ConsultingSpace EconomySpace Finance Community
Share

Key takeaways

01

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

02

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

In this episode, Kevin O’Connell discussed his career in government that led to his present business of informing and defining space commerce as a consultant for companies throughout the globe. As founder and CEO of Space Economy Rising, LLC, O’Connell speaks to the past and future of space commerce. With decades of experience working within government institutions, including the White House as well as speaking before US Congress committees on a variety of issues, O’Connell is uniquely positioned to provide insight into an industry that is both elusive and relevant.

When asked about his transition to the private sector, O’Connell spoke to his decision as follows:

“We’ve had a lot of folks talk to us over the last few years to say hey Kevin you just have to slow this all down. You have to slow all of this work down, especially in lower earth orbit. And, our view was that we looked very hard for data driven approaches to regulation we were going to regulate. What would be the analytic basis upon which we would do it.

We worked with the FCC when they issued their orbital debris mitigation guidelines to say okay what pieces of this rule are supported by what kinds of evidence. And, in a lot of cases there was a lot of wishful thinking but there wasn’t a lot of data rigorously collected to support that. And I would say that regulation that is uninformed and just based on wishful thinking can really do tremendous damage to an industry. So, you have to think about it that way. I think you do.”

This intriguing podcast goes on to explore O’Connell’s transition out of government and to what he is doing now in the private sector as well as what lessons he is bringing forward into his present business.

Of the many hats O’Connell wears, the most significant of his present contributions is in the field of space economy. This includes advising companies on

  • Space Industry
  • Technology
  • Space finance community
  • Basics that must be done as an early-stage company in this field
  • Competitors
  • Orbital debris mitigation strategies
  • Cyber security strategies
  • Investment Risk Management
  • And much more.

Tune in to learn from this renowned expert as the discussion covers everything from how he got to where he is to what he envisions for the future of space economy.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

PharmaLogic is buying Lantheus' contract manufacturing unit and Springfield, New Jersey radiopharmaceutical plant, plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Radioligand developers looking for capacity should ask how much of the plant's capacity is still open.

  • 01A long-term supply contract attached to a plant sale could help keep costly hot-cell capacity in use. According to Grand View Research, committed supply agreements are among the tools that help providers align capital spending with customer development milestones.
  • 02Radioligand developers evaluating PharmaLogic's Agilera unit should ask how much Springfield capacity the lutetium Lu 177 dotatate contract will take up and how much is left for new programs.
  • 03Two pending transactions shape what to watch next: regulatory review and closing conditions for the PharmaLogic purchase, and Curium’s August offer of upward of $8 billion for Lantheus, which is still closing.

Nov 18, 2026

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA moves Rapid Micro’s Growth Direct from distribution to ownership for QC labs

Merck KGaA agreed to buy Rapid Micro Biosystems, maker of the Growth Direct microbial testing platform, for $0.75 per share in cash. The deal turns a 2025 distribution partnership into ownership. Growth Direct instruments, consumables and software would then come from the company that already sells QC products to pharma labs, pending a December 2026 close.

  • 01Growth Direct shifts from a Merck-distributed product, under a February 2025 agreement, to a Merck-owned one inside a QC portfolio that spans environmental monitoring, in-process and release testing.
  • 02For labs that already run Growth Direct alongside MilliporeSigma QC products, the useful question is how the platform's digital sample records will connect to the rest of that workflow after close.
  • 03The next date to watch is the Schedule TO filing that opens the tender offer; closing targeted for December 2026 requires a majority of Rapid Micro’s voting shares to be tendered.

Nov 17, 2026

SR-Tiget gene therapy families average six months in Milan, with years of follow-up testing

SR-Tiget gene therapy families average six months in Milan, with years of follow-up testing

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03A practical question for gene therapy services: who alerts the lab when a child’s fever delays a blood draw? At SR-Tiget, research nurses manage the patient schedule and coordinate sample timing with the lab.

Nov 16, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512